Comparison of Pterygium Recurrence with and without Using Postsurgical Topical Cyclosporin A 0.05%: A Randomized...

Area of Science:

• Ophthalmology
• Surgical Innovation
• Clinical Trials

Background:

• Pterygium surgery, often using mitomycin C (MMC) and conjunctival flaps, aims to prevent recurrence.
• Postoperative inflammation and recurrence remain challenges in pterygium management.

Purpose of the Study:

• To assess the efficacy of 3-month topical cyclosporin A (CsA) 0.05% in preventing pterygium recurrence post-surgery.
• To evaluate the impact of CsA on postoperative inflammation and complications.

Main Methods:

• A randomized, single-blind clinical trial involving 78 patients undergoing pterygium surgery with the rotational conjunctival flap technique and MMC.
• Patients were allocated to either a control group or a case group receiving CsA 0.05% for 3 months.
• Outcomes including visual acuity, intraocular pressure, inflammation, complications, and recurrence were monitored up to 6 months postoperatively.

Main Results:

• No significant differences were observed in clinical inflammation between the CsA and control groups at 1 and 3 months postoperatively (P = 0.108 and P = 0.780).
• Complication rates were similar between the groups (P = 0.99), with no serious adverse events reported.
• The pterygium recurrence rate was comparable: 5.1% in the CsA group versus 7.7% in the control group (P = 0.99).

Conclusions:

• Three-month administration of topical CsA 0.05% demonstrated no significant benefit in preventing pterygium recurrence after surgery.
• CsA 0.05% did not show a priority for improving postoperative outcomes, including inflammation and complication rates, in this surgical technique.